BeOne Medicines (ONC) Cost of Revenue (2017 - 2026)

BeOne Medicines (ONC) has reported Cost of Revenue for 10 consecutive years, with $167.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 1.34% year-over-year to $167.2 million; the TTM figure through Mar 2026 stood at $670.8 million (up 5.77% YoY), while the FY2025 annual figure was $668.5 million, up 12.53% from the prior year.
• Cost of Revenue climbed to $167.2 million in Q1 2026 per ONC's latest filing, from $142.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $196.5 million in Q3 2025 and bottomed at $65.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $123.3 million across 5 years, with a median of $124.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 99.59% — and 2025, when it dropped 11.3%.
• BeOne Medicines' Cost of Revenue stood at $73.5 million in 2022, then surged by 43.95% to $105.8 million in 2023, then surged by 51.71% to $160.6 million in 2024, then declined by 11.3% to $142.4 million in 2025, then gained by 17.41% to $167.2 million in 2026.
• Business Quant data shows ONC's Cost of Revenue at $167.2 million in Q1 2026, $142.4 million in Q4 2025, and $196.5 million in Q3 2025.